Liver transplantation in human immunodeficiency virus/hepatitis C virus–coinfected patients: Response needed!
John G. O'Grady – 19 March 2012
Rabbit anti‐thymocyte globulin in liver transplantation: All that glitters is not gold, but 1000 patients are so many to dazzle
Marina Berenguer, José‐Antonio Pons – 19 March 2012
Hemodynamics‐compliant reconstruction of the right hepatic vein for adult living donor liver transplantation with a right liver graft
Shin Hwang, Tae‐Yong Ha, Chul‐Soo Ahn, Deok‐Bog Moon, Gi‐Won Song, Ki‐Hun Kim, Dong‐Hwan Jung, Gil‐Chun Park, Kyu‐Bo Sung, Gi‐Young Ko, Kyoung Won Kim, Byungchul Cho, Jung‐Man Namgoong, Sung‐Won Jung, Sam‐Youl Yoon, Chun‐Soo Park, Yo‐Han Park, Hyeong‐Woo Park, Hyo‐Jun Lee, Sung‐Gyu Lee – 16 March 2012 – Secure reconstruction of the right hepatic vein (RHV) is essential for the successful implantation of a right liver graft during living donor liver transplantation (LDLT).
Immediate intraportal transplantation of human bone marrow mesenchymal stem cells prevents death from fulminant hepatic failure in pigs
Jun Li, Liyuan Zhang, Jiaojiao Xin, Longyan Jiang, Jun Li, Ting Zhang, Linfeng Jin, Jianzhou Li, Pengcheng Zhou, Shaorui Hao, Hongcui Cao, Lanjuan Li – 16 March 2012 – The effectiveness of human bone marrow mesenchymal stem cell (hBMSC) transplantation to treat acute and chronic liver injury has been demonstrated in animal models and in a few nonrandomized clinical trials. However, no studies have investigated hBMSC transplantation in the treatment of fulminant hepatic failure (FHF), especially in large animal (pig) models.
Not all types of acute kidney injury are equal in the setting of liver transplantation
Milind Junghare, Hassan N. Ibrahim – 16 March 2012
Reply
Long H. Nguyen, Mindie Nguyen – 16 March 2012
Prevention of de novo hepatitis B with adefovir dipivoxil in recipients of liver grafts from hepatitis B core antibody–positive donors
Matthew S. Chang, Sonja K. Olsen, Elsa M. Pichardo, Scott Heese, Jessica B. Stiles, Rita Abdelmessih, Elizabeth C. Verna, James V. Guarrera, Jean C. Emond, Robert S. Brown – 16 March 2012 – Lamivudine has been shown to prevent de novo hepatitis B virus (HBV) infections in liver transplantation (LT) patients receiving hepatitis B core antibody–positive (HBcAb+) grafts, but it may produce long‐term resistance. Adefovir dipivoxil (ADV) might be effective in preventing de novo hepatitis and resistance.
A ZFN/piggyBac step closer to autologous liver cell therapy
Aras N. Mattis, Holger Willenbring – 15 March 2012
Clinical cofactors and hepatic fibrosis in hereditary hemochromatosis: The role of diabetes mellitus
Marnie J. Wood, Lawrie W. Powell, Jeannette L. Dixon, Grant A. Ramm – 15 March 2012 – The risk of hepatic fibrosis and cirrhosis in hereditary hemochromatosis relates to the degree of iron loading, but iron alone does not explain the variability in disease penetrance. This study sought to identify clinical cofactors that increase the risk of progressive liver disease. We identified 291 patients from our database who were homozygous for the C282Y mutation in HFE and had undergone a liver biopsy with quantification of hepatic iron concentration (HIC) and fibrosis staging.
A large case‐control study on the predictability of hepatitis B surface antigen levels three years before hepatitis B surface antigen seroclearance
Wai‐Kay Seto, Danny Ka‐Ho Wong, James Fung, Ivan Fan‐Ngai Hung, Daniel Yee‐Tak Fong, John Chi‐Hang Yuen, Teresa Tong, Ching‐Lung Lai, Man‐Fung Yuen – 15 March 2012 – The kinetics of hepatitis B surface antigen (HBsAg) levels preceding spontaneous HBsAg seroclearance has not been fully investigated. The kinetics of HBsAg and hepatitis B virus (HBV) DNA of 203 treatment‐naïve, hepatitis B e antigen (HBeAg)‐negative patients with spontaneous HBsAg seroclearance were compared with 203 age‐ and sex‐matched HBeAg‐negative controls.